NO20013115L - En kombinasjon av FBPase inhibitorer og insulinsensibilisatorer for behandling av diabetes - Google Patents

En kombinasjon av FBPase inhibitorer og insulinsensibilisatorer for behandling av diabetes

Info

Publication number
NO20013115L
NO20013115L NO20013115A NO20013115A NO20013115L NO 20013115 L NO20013115 L NO 20013115L NO 20013115 A NO20013115 A NO 20013115A NO 20013115 A NO20013115 A NO 20013115A NO 20013115 L NO20013115 L NO 20013115L
Authority
NO
Norway
Prior art keywords
diabetes
treatment
combination
insulin
insulin sensitizers
Prior art date
Application number
NO20013115A
Other languages
English (en)
Norwegian (no)
Other versions
NO20013115D0 (no
Inventor
Mark D Erion
Paul Van Poelje
Original Assignee
Metabasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc filed Critical Metabasis Therapeutics Inc
Publication of NO20013115D0 publication Critical patent/NO20013115D0/no
Publication of NO20013115L publication Critical patent/NO20013115L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
NO20013115A 1998-12-24 2001-06-21 En kombinasjon av FBPase inhibitorer og insulinsensibilisatorer for behandling av diabetes NO20013115L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11471898P 1998-12-24 1998-12-24
PCT/US1999/030713 WO2000038666A2 (fr) 1998-12-24 1999-12-22 COMBINAISON D'INHIBITEURS DE LA FBPase ET DE SENSIBILISANTS A L'INSULINE, POUR LE TRAITEMENT DU DIABETE

Publications (2)

Publication Number Publication Date
NO20013115D0 NO20013115D0 (no) 2001-06-21
NO20013115L true NO20013115L (no) 2001-08-24

Family

ID=22357016

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013115A NO20013115L (no) 1998-12-24 2001-06-21 En kombinasjon av FBPase inhibitorer og insulinsensibilisatorer for behandling av diabetes

Country Status (25)

Country Link
EP (1) EP1143955B1 (fr)
JP (1) JP2003515523A (fr)
KR (3) KR20060114724A (fr)
CN (3) CN1714866A (fr)
AT (1) ATE300288T1 (fr)
AU (1) AU771039B2 (fr)
BR (1) BR9917005A (fr)
CA (1) CA2354053A1 (fr)
CZ (1) CZ20012353A3 (fr)
DE (1) DE69926400T2 (fr)
DK (1) DK1143955T3 (fr)
ES (1) ES2246586T3 (fr)
HK (1) HK1046863B (fr)
HU (1) HUP0402506A3 (fr)
ID (1) ID30237A (fr)
IL (2) IL143569A0 (fr)
MX (1) MXPA01006511A (fr)
NO (1) NO20013115L (fr)
NZ (1) NZ512219A (fr)
PL (1) PL352756A1 (fr)
PT (1) PT1143955E (fr)
RU (2) RU2227749C2 (fr)
SK (1) SK9172001A3 (fr)
WO (1) WO2000038666A2 (fr)
ZA (1) ZA200105016B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039344A1 (fr) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Nouveaux composes de purine inhibiteurs de fructose-1,6-biophasphatase
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
WO2000014095A1 (fr) 1998-09-09 2000-03-16 Metabasis Therapeutics, Inc. Nouveaux inhibiteurs heteroaromatiques de fructose-1,6-biphosphatase
EP1240174A2 (fr) * 1999-12-22 2002-09-18 Metabasis Therapeutics, Inc. Promedicaments a base de bisamidate phosphonate
DE60125734T2 (de) * 2000-03-08 2007-10-25 Metabasis Therapeutics, Inc., La Jolla Neue aryl fructose-1,6-bisphosphatase inhibitoren
KR100854851B1 (ko) * 2000-07-06 2008-08-27 메타베이시스 테라퓨틱스, 인크. 당뇨병 치료에 유용한 ＦＢＰａｓｅ 억제제와 항당뇨제의조합물
US7022725B2 (en) 2000-11-17 2006-04-04 Takeda Pharmaceutical Company Limited Isoxazole derivatives
NZ536328A (en) 2002-05-13 2007-11-30 Metabasis Therapeutics Inc Novel phosphonic acid based prodrugs of PMEA and its analogues
EP1504014B1 (fr) 2002-05-13 2015-12-02 Metabasis Therapeutics, Inc. Procede d'elaboration de promedicaments cycliques de pmea et de pmpa
JP4719465B2 (ja) * 2002-09-04 2011-07-06 ディーエスエム アイピー アセッツ ビー．ブイ． インスリン感受性増強剤およびペプチド画分を含む栄養補給用および治療用組成物
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
CA2515726C (fr) * 2003-02-11 2012-07-10 Vernalis (Cambridge) Limited Isoxazoles
EP3002283B1 (fr) * 2003-12-26 2017-06-14 Kyowa Hakko Kirin Co., Ltd. Dérivés de thiazole
WO2006023515A2 (fr) * 2004-08-18 2006-03-02 Metabasis Therapeutics, Inc. Nouveaux inhibiteurs thiazole de la fructose 1,6-bisphosphatase
WO2006064744A1 (fr) * 2004-12-13 2006-06-22 Daiichi Sankyo Company, Limited Composition medicinale pour le traitement du diabete
TW200633702A (en) * 2004-12-15 2006-10-01 Sankyo Co Medicinal composition containing fbpase inhibitor
EP1889618A4 (fr) * 2005-05-27 2010-11-24 Daiichi Sankyo Co Ltd Médicament combiné pour le traitement du diabète
US20100280023A1 (en) 2005-06-23 2010-11-04 Kyowa Hakko Kogyo Co., Ltd. Thiazole derivatives
EP2089017A2 (fr) 2006-11-02 2009-08-19 Aestus Therapeutics, Inc. Procédés de traitement de la douleur neuropathique par la modulation des voies de la glycogénolyse ou de la glycolyse
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
US9631825B2 (en) 2012-12-18 2017-04-25 Nortek Air Solutions, Llc Air filter assembly
JP2017512183A (ja) 2014-02-13 2017-05-18 リガンド・ファーマシューティカルズ・インコーポレイテッド プロドラッグ化合物およびそれらの使用
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
CN105481896A (zh) * 2015-12-03 2016-04-13 浙江大学 一种地马格列的制备方法
CN113416739B (zh) * 2021-06-24 2022-04-19 黑龙江八一农垦大学 鲁氏酵母菌基因在提高微生物产hdmf的产量中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968790A (en) * 1988-08-12 1990-11-06 American Cyanamid Company Antidiabetic phosphates
JPH03157377A (ja) * 1988-11-18 1991-07-05 Takeda Chem Ind Ltd チオ尿素誘導体及びａｇｅ生成阻害剤
CA2008325A1 (fr) * 1989-01-24 1990-07-24 Harry E. Gruber Methode et compose pour la liberation de ribosides et l'abaissement de la glycemie
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
WO1998039344A1 (fr) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Nouveaux composes de purine inhibiteurs de fructose-1,6-biophasphatase
AU6691498A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase
AU6691798A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase

Also Published As

Publication number Publication date
AU2058300A (en) 2000-07-31
MXPA01006511A (es) 2004-03-19
ES2246586T3 (es) 2006-02-16
HK1046863A1 (en) 2003-01-30
KR20070046210A (ko) 2007-05-02
KR20060114724A (ko) 2006-11-07
IL143569A (en) 2006-06-11
HK1046863B (zh) 2008-07-25
CZ20012353A3 (cs) 2001-12-12
ID30237A (id) 2001-11-15
SK9172001A3 (en) 2002-04-04
ATE300288T1 (de) 2005-08-15
KR20010099942A (ko) 2001-11-09
WO2000038666A2 (fr) 2000-07-06
RU2003132054A (ru) 2005-04-20
HUP0402506A3 (en) 2007-05-29
PT1143955E (pt) 2005-11-30
PL352756A1 (en) 2003-09-08
DK1143955T3 (da) 2005-11-14
CN100352505C (zh) 2007-12-05
DE69926400D1 (de) 2005-09-01
EP1143955B1 (fr) 2005-07-27
JP2003515523A (ja) 2003-05-07
AU771039B2 (en) 2004-03-11
EP1143955A2 (fr) 2001-10-17
HUP0402506A2 (hu) 2005-04-28
WO2000038666A3 (fr) 2001-11-29
NZ512219A (en) 2004-12-24
EP1143955A3 (fr) 2002-08-28
BR9917005A (pt) 2002-04-02
CA2354053A1 (fr) 2000-07-06
KR100689943B1 (ko) 2007-03-08
RU2227749C2 (ru) 2004-04-27
DE69926400T2 (de) 2006-05-24
NO20013115D0 (no) 2001-06-21
CN1714866A (zh) 2006-01-04
CN101164618A (zh) 2008-04-23
CN1350466A (zh) 2002-05-22
ZA200105016B (en) 2002-09-19
IL143569A0 (en) 2002-04-21

Similar Documents

Publication Publication Date Title
NO20013115L (no) En kombinasjon av FBPase inhibitorer og insulinsensibilisatorer for behandling av diabetes
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
HK1070575A1 (en) Use of botulinum toxin for treating cardiovasculardiseases
HK1059213A1 (en) Treatment of type 2 diabetes with inhibitors of dipetidyl peptidase iv
NO20061736L (no) Krystallform av epotilon B
ATE413386T1 (de) Ppar-gamma modulatoren
NO20055832L (no) Fremstilling og anvendelse av arylalkylsyrederivater for behandling av fedme
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
SG146653A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
ATE408601T1 (de) Fredericamycin-derivate
DK1426054T3 (da) Medicinsk anvendelse af histon-deacetylase-inhibitor og fremgangsmåde til evaluering af antitumor virkning deraf
NO20045056L (no) Fremgangsmater for behandling av hepatitt
NO20045354L (no) Fremgangsmater for behandling av angiogenese, turmorvekst og metastaser
HK1064950A1 (en) Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
AU7564396A (en) Rac-proteine kinase as therapeutic agent or in diagnostics
IL186356A0 (en) Method of treating of preventing type-2 diabetes
WO2003035048A3 (fr) Procedes et compositions de traitement de l'osteo-arthrite
NO20003813L (no) FremgangsmÕter for Õ redusere eller forhindre smerte ved bruk av spicamycin eller derivater derav
UA35854A (uk) Спосіб лікування приховано протікаючого силікотуберкульозу

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application